ArticleAnnals of medicine and surgery (2012)2026
Efficacy of brolucizumab and ranibizumab in diabetic macular edema and neovascular age-related macular degeneration: insights from a case series.
Article in Annals of medicine and surgery (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The effectiveness of various anti-vascular endothelial growth factors in treating patients with diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) in Bangladesh lacks comprehensive information. Objective: We evaluated the efficacy of brolucizumab and ranibizumab and assessed the incidence of drug-related adverse events in nAMD and DME patients of Bangladesh. Methods: In this retrospective case series, 20 patients who had received either intravitreal brolucizumab (n = 10) or ranibizumab (n = 10) were included. Demographic and clinical characteristics, data on best-corrected visual acuity (BCVA), and optical coherence tomography (OCT) measurements, including macular volume (MV) and central subfield retinal thickness (CSRT), were recorded for each patient at baseline and follow-up visits. In addition, brolucizumab was compared with ranibizumab in terms of above mentioned parameters. Results: Both brolucizumab and ranibizumab induced changes in patient parameters, including BCVA, OCT measurements, and MV, relative to baseline values. At the 12-week follow-up, neither drug demonstrated statistically significant superiority over the other ( Conclusion: Intravitreal brolucizumab appeared to be an effective option for patients with nAMD and DME.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.